A Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices in Comparison With 0.24% Sodium Fluoride (1100 Ppm F) Dentifrice Control in 10 to 14-year-old Children

Overview

The objective of this study is to assess the safety and to evaluate the anti-caries efficacy of COL101 (arginine) non-fluoride dentifrices compared to a 0.24% sodium fluoride dentifrice in 10-14 year-old children over a one year period.

Full Title of Study: “A Phase 2 Randomized, Double-blind, Active-controlled Multi-center Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices With 1.5%, 4.0% and 8.0% Arginine Each in Comparison With 0.24% Sodium Fluoride (1100 Ppm F) Dentifrice Control in 10 to 14-year-old Children”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: March 2024

Interventions

  • Drug: 0.24% Sodium Fluoride Dentifrice
    • Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
  • Drug: 1.5% Arginine Dentifrice
    • Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
  • Drug: 4.0% Arginine Dentifrice
    • Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
  • Drug: 8.0% Arginine Dentifrice
    • Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study

Arms, Groups and Cohorts

  • Active Comparator: 0.24% Sodium Fluoride Dentifrice
    • Toothpaste
  • Experimental: 1.5% Arginine Dentifrice
    • Toothpaste
  • Experimental: 4.0% Arginine Dentifrice
    • Toothpaste
  • Experimental: 8.0% Arginine Dentifrice
    • Toothpaste

Clinical Trial Outcome Measures

Primary Measures

  • The primary efficacy endpoint will be the incremental subject-wise Decayed Missing Filled Surfaces (DMFS) score after one year of product use
    • Time Frame: one year
    • the minimum score is 0, maximum score is 4/5 depending on the tooth number and a higher score represents a worse outcome

Secondary Measures

  • Incremental subject-wise Decayed Missing Filled Surfaces (DFMS) score after 6-months of product use;
    • Time Frame: after 6 months
    • the minimum score is 0, maximum score is 4/5 depending on the tooth number and a higher score represents a worse outcome
  • Incremental subject-wise Decayed Missing Filled Surfaces (DFMS) score between 6- months and one year of product use.
    • Time Frame: between 6-months and one year
    • the minimum score is 0, maximum score is 4/5 depending on the tooth number and a higher score represents a worse outcome
  • Clinically significant change in International Caries Detection and Assessment System (ICDAS) severity scores between the baseline and the six-month and one-year examinations and between the six-month and one-year examinations.
    • Time Frame: between 6-months and one year
    • the minimum score is 0, maximum score is 6 and a higher score represents a worse outcome
  • Clinically significant changes indicating caries progression are changes in ICDAS severity values from 0 to 2 or higher, from 1 or 2 to 3 or higher, or from 3 or 4 to 5 or 6.
    • Time Frame: 6 months
  • Clinically significant changes indicating caries regression are changes in ICDAS severity values from 2 or higher to 0 or 1.
    • Time Frame: 12 months

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects meeting all criteria below will be included in the study: 1. Subject assent and parental/guardian informed consent for voluntary participation. 2. Willingness and ability to use the assigned products according to instructions, availability for all appointments and likelihood of completing the clinical trial. 3. Children ages 10-14 years at baseline. 4. Presence of permanent second molars or evidence of at least one permanent second molar erupting as indicated by cuspal break through the mucosa. 5. Good general health as evidenced by a review of the medical history. 6. Subjects who, at study entry, have present two or more active caries lesions (ICDAS scores of 2 or greater) in permanent teeth and previous caries experience (DMFT >1), D= Decayed is defined as ICDAS scores of 3 or greater Exclusion Criteria:

  • Subjects presenting any of the criteria below will be excluded from the study: 1. Presence of fixed or removable prosthetic appliance or orthodontic treatment involving more than four permanent teeth. 2. Use of medication that could increase the risk of developing dental caries, i.e. medications that reduce saliva flow and those with high sugar content. 3. Long-term antibiotic therapy. 4. Children with a confirmed diagnosis of cognitive and/or motor impairment. 5. Severe malocclusion. 6. Subjects who, at study entry, have present severe caries (ICDAS 5 or 6) on five or more permanent teeth. 7. Evidence of moderate to severe periodontal disease. 8. Participation in any other clinical study within the 30 days preceding the start of the clinical study. 9. Known history of allergies or other adverse reactions to arginine, or oral care products, or their ingredients. 10. Self-reported history of being currently pregnant, intending to become pregnant during the trial period or breast-feeding.

Gender Eligibility: All

Minimum Age: 10 Years

Maximum Age: 14 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Colgate Palmolive
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Maria E Ryan, DDS PhD, Study Director, Colgate-Palmolive Company

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.